Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer

A randomized trial

Saroj Vadhan-Raj, Jonathan Trent, Shreyaskumar Patel, Xiao Zhou, Marcella M. Johnson, Dejka Araujo, Joseph A. Ludwig, Shana O'Roark, Ann M. Gillenwater, Carlos Bueso-Ramos, Adel K. El-Naggar, Robert S. Benjamin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Mucositis can be a serious complication of cancer treatment. Palifermin reduces mucositis when given in multiple doses to patients undergoing hematopoietic stem-cell transplantation. Objective: To evaluate the efficacy of palifermin given as a single dose before each cycle in patients receiving multicycle chemotherapy. Design: Randomized, double-blind, placebo-controlled trial. (Clinical Trials.gov registration number: NCT00267046) Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Patients: 48 patients with sarcoma were randomly assigned in a 2:1 ratio to receive palifermin or placebo. All patients received doxorubicin-based chemotherapy (90 mg per m2 of body surface area over 3 days, by infusion). Intervention: Palifermin (180 μg per kg of body weight) or placebo was administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles). Patients who had severe mucositis received open-label palifermin in subsequent cycles. Measurements: Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale (grades 0 to 4), with moderate to severe mucositis (grades 2 to 4) as the main outcomes; patient-reported outcome questionnaire; and daily symptom record diary. Results: A median of 6 blinded cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo group. Compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44% vs. 88%; P < 0.001; difference, -44 percentage points [95% CI, -71 to -16 percentage points) and severe (grade 3 or 4) mucositis (13% vs. 51%; P = 0.002; difference, -38 percentage points [CI, -67 to -9 percentage points]). The main adverse effects were thickening of oral mucosa (72% in the palifermin group vs. 31% in the placebo group; P = 0.007) and altered taste. Seven of the 8 patients who had severe mucositis in the placebo group received open-label palifermin. None of these patients had severe mucositis in the subsequent cycles (a total of 17) with open-label palifermin. Limitations: Study limitations include smaller sample size for the control group, inclusion of only patients with sarcoma, and perceived unblinding of the treatment because of notable differences between the biologic effects of palifermin and placebo. Conclusion: A single dose of palifermin before each cycle reduced the incidence and severity of mucositis. The drug was generally well tolerated, but most patients experienced thickening of oral mucosa. Further investigation is needed to determine whether palifermin use will facilitate greater adherence to chemotherapy regimens by reducing mucositis. Primary Funding Source: Amgen.

Original languageEnglish
Pages (from-to)358-367
Number of pages10
JournalAnnals of Internal Medicine
Volume153
Issue number6
StatePublished - Sep 21 2010
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 7
Stomatitis
Mucositis
Drug Therapy
Neoplasms
Placebos
Mouth Mucosa
Sarcoma
Dysgeusia
Placebo Effect
Body Surface Area
Hematopoietic Stem Cell Transplantation
Incidence
Sample Size
Doxorubicin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Vadhan-Raj, S., Trent, J., Patel, S., Zhou, X., Johnson, M. M., Araujo, D., ... Benjamin, R. S. (2010). Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: A randomized trial. Annals of Internal Medicine, 153(6), 358-367.

Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer : A randomized trial. / Vadhan-Raj, Saroj; Trent, Jonathan; Patel, Shreyaskumar; Zhou, Xiao; Johnson, Marcella M.; Araujo, Dejka; Ludwig, Joseph A.; O'Roark, Shana; Gillenwater, Ann M.; Bueso-Ramos, Carlos; El-Naggar, Adel K.; Benjamin, Robert S.

In: Annals of Internal Medicine, Vol. 153, No. 6, 21.09.2010, p. 358-367.

Research output: Contribution to journalArticle

Vadhan-Raj, S, Trent, J, Patel, S, Zhou, X, Johnson, MM, Araujo, D, Ludwig, JA, O'Roark, S, Gillenwater, AM, Bueso-Ramos, C, El-Naggar, AK & Benjamin, RS 2010, 'Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: A randomized trial', Annals of Internal Medicine, vol. 153, no. 6, pp. 358-367.
Vadhan-Raj, Saroj ; Trent, Jonathan ; Patel, Shreyaskumar ; Zhou, Xiao ; Johnson, Marcella M. ; Araujo, Dejka ; Ludwig, Joseph A. ; O'Roark, Shana ; Gillenwater, Ann M. ; Bueso-Ramos, Carlos ; El-Naggar, Adel K. ; Benjamin, Robert S. / Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer : A randomized trial. In: Annals of Internal Medicine. 2010 ; Vol. 153, No. 6. pp. 358-367.
@article{aaa09182ff2b41fa8a0f989a2a0ddfe0,
title = "Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: A randomized trial",
abstract = "Background: Mucositis can be a serious complication of cancer treatment. Palifermin reduces mucositis when given in multiple doses to patients undergoing hematopoietic stem-cell transplantation. Objective: To evaluate the efficacy of palifermin given as a single dose before each cycle in patients receiving multicycle chemotherapy. Design: Randomized, double-blind, placebo-controlled trial. (Clinical Trials.gov registration number: NCT00267046) Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Patients: 48 patients with sarcoma were randomly assigned in a 2:1 ratio to receive palifermin or placebo. All patients received doxorubicin-based chemotherapy (90 mg per m2 of body surface area over 3 days, by infusion). Intervention: Palifermin (180 μg per kg of body weight) or placebo was administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles). Patients who had severe mucositis received open-label palifermin in subsequent cycles. Measurements: Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale (grades 0 to 4), with moderate to severe mucositis (grades 2 to 4) as the main outcomes; patient-reported outcome questionnaire; and daily symptom record diary. Results: A median of 6 blinded cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo group. Compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44{\%} vs. 88{\%}; P < 0.001; difference, -44 percentage points [95{\%} CI, -71 to -16 percentage points) and severe (grade 3 or 4) mucositis (13{\%} vs. 51{\%}; P = 0.002; difference, -38 percentage points [CI, -67 to -9 percentage points]). The main adverse effects were thickening of oral mucosa (72{\%} in the palifermin group vs. 31{\%} in the placebo group; P = 0.007) and altered taste. Seven of the 8 patients who had severe mucositis in the placebo group received open-label palifermin. None of these patients had severe mucositis in the subsequent cycles (a total of 17) with open-label palifermin. Limitations: Study limitations include smaller sample size for the control group, inclusion of only patients with sarcoma, and perceived unblinding of the treatment because of notable differences between the biologic effects of palifermin and placebo. Conclusion: A single dose of palifermin before each cycle reduced the incidence and severity of mucositis. The drug was generally well tolerated, but most patients experienced thickening of oral mucosa. Further investigation is needed to determine whether palifermin use will facilitate greater adherence to chemotherapy regimens by reducing mucositis. Primary Funding Source: Amgen.",
author = "Saroj Vadhan-Raj and Jonathan Trent and Shreyaskumar Patel and Xiao Zhou and Johnson, {Marcella M.} and Dejka Araujo and Ludwig, {Joseph A.} and Shana O'Roark and Gillenwater, {Ann M.} and Carlos Bueso-Ramos and El-Naggar, {Adel K.} and Benjamin, {Robert S.}",
year = "2010",
month = "9",
day = "21",
language = "English",
volume = "153",
pages = "358--367",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer

T2 - A randomized trial

AU - Vadhan-Raj, Saroj

AU - Trent, Jonathan

AU - Patel, Shreyaskumar

AU - Zhou, Xiao

AU - Johnson, Marcella M.

AU - Araujo, Dejka

AU - Ludwig, Joseph A.

AU - O'Roark, Shana

AU - Gillenwater, Ann M.

AU - Bueso-Ramos, Carlos

AU - El-Naggar, Adel K.

AU - Benjamin, Robert S.

PY - 2010/9/21

Y1 - 2010/9/21

N2 - Background: Mucositis can be a serious complication of cancer treatment. Palifermin reduces mucositis when given in multiple doses to patients undergoing hematopoietic stem-cell transplantation. Objective: To evaluate the efficacy of palifermin given as a single dose before each cycle in patients receiving multicycle chemotherapy. Design: Randomized, double-blind, placebo-controlled trial. (Clinical Trials.gov registration number: NCT00267046) Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Patients: 48 patients with sarcoma were randomly assigned in a 2:1 ratio to receive palifermin or placebo. All patients received doxorubicin-based chemotherapy (90 mg per m2 of body surface area over 3 days, by infusion). Intervention: Palifermin (180 μg per kg of body weight) or placebo was administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles). Patients who had severe mucositis received open-label palifermin in subsequent cycles. Measurements: Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale (grades 0 to 4), with moderate to severe mucositis (grades 2 to 4) as the main outcomes; patient-reported outcome questionnaire; and daily symptom record diary. Results: A median of 6 blinded cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo group. Compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44% vs. 88%; P < 0.001; difference, -44 percentage points [95% CI, -71 to -16 percentage points) and severe (grade 3 or 4) mucositis (13% vs. 51%; P = 0.002; difference, -38 percentage points [CI, -67 to -9 percentage points]). The main adverse effects were thickening of oral mucosa (72% in the palifermin group vs. 31% in the placebo group; P = 0.007) and altered taste. Seven of the 8 patients who had severe mucositis in the placebo group received open-label palifermin. None of these patients had severe mucositis in the subsequent cycles (a total of 17) with open-label palifermin. Limitations: Study limitations include smaller sample size for the control group, inclusion of only patients with sarcoma, and perceived unblinding of the treatment because of notable differences between the biologic effects of palifermin and placebo. Conclusion: A single dose of palifermin before each cycle reduced the incidence and severity of mucositis. The drug was generally well tolerated, but most patients experienced thickening of oral mucosa. Further investigation is needed to determine whether palifermin use will facilitate greater adherence to chemotherapy regimens by reducing mucositis. Primary Funding Source: Amgen.

AB - Background: Mucositis can be a serious complication of cancer treatment. Palifermin reduces mucositis when given in multiple doses to patients undergoing hematopoietic stem-cell transplantation. Objective: To evaluate the efficacy of palifermin given as a single dose before each cycle in patients receiving multicycle chemotherapy. Design: Randomized, double-blind, placebo-controlled trial. (Clinical Trials.gov registration number: NCT00267046) Setting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Patients: 48 patients with sarcoma were randomly assigned in a 2:1 ratio to receive palifermin or placebo. All patients received doxorubicin-based chemotherapy (90 mg per m2 of body surface area over 3 days, by infusion). Intervention: Palifermin (180 μg per kg of body weight) or placebo was administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles). Patients who had severe mucositis received open-label palifermin in subsequent cycles. Measurements: Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale (grades 0 to 4), with moderate to severe mucositis (grades 2 to 4) as the main outcomes; patient-reported outcome questionnaire; and daily symptom record diary. Results: A median of 6 blinded cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo group. Compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44% vs. 88%; P < 0.001; difference, -44 percentage points [95% CI, -71 to -16 percentage points) and severe (grade 3 or 4) mucositis (13% vs. 51%; P = 0.002; difference, -38 percentage points [CI, -67 to -9 percentage points]). The main adverse effects were thickening of oral mucosa (72% in the palifermin group vs. 31% in the placebo group; P = 0.007) and altered taste. Seven of the 8 patients who had severe mucositis in the placebo group received open-label palifermin. None of these patients had severe mucositis in the subsequent cycles (a total of 17) with open-label palifermin. Limitations: Study limitations include smaller sample size for the control group, inclusion of only patients with sarcoma, and perceived unblinding of the treatment because of notable differences between the biologic effects of palifermin and placebo. Conclusion: A single dose of palifermin before each cycle reduced the incidence and severity of mucositis. The drug was generally well tolerated, but most patients experienced thickening of oral mucosa. Further investigation is needed to determine whether palifermin use will facilitate greater adherence to chemotherapy regimens by reducing mucositis. Primary Funding Source: Amgen.

UR - http://www.scopus.com/inward/record.url?scp=77957343771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957343771&partnerID=8YFLogxK

M3 - Article

VL - 153

SP - 358

EP - 367

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -